1. Key Insights 2. Spinocerebellar Ataxia Market Overview at a Glance 2.1. Market Share (%) Distribution of Spinocerebellar Ataxia in 2017 2.2. Market Share (%) Distribution of Spinocerebellar Ataxia in 2028 3. Disease Background and Overview 3.1. Introduction 3.2. Subtypes of SCA 3.2.1. SCA1 3.2.2. SCA2 3.2.3. SCA3 3.2.4. SCA6 3.2.5. SCA7 3.3. Causes and risk factors 3.4. History 3.5. Signs and Symptoms 3.6. Pathophysiology 3.7. Diagnosis 3.8. Biomarkers 3.8.1. Neuroimaging biomarkers 3.8.2. Oculomotor biomarkers 3.8.3. Biological biomarkers 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. 7MM Total Patient Population of Spinocerebellar Ataxia 5. Country Wise-Epidemiology of Spinocerebellar Ataxia 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Total Prevalent Population of Spinocerebellar Ataxia in the United States 5.1.3. Total Diagnosed Cases of Spinocerebellar Ataxia in the United States 5.1.4. Type-Specific Prevalence of Spinocerebellar Ataxia in the United States 5.2. EU5 Countries 5.2.1. Assumptions and Rationale 5.3. Germany 5.3.1. Total Prevalent Population of Spinocerebellar Ataxia in Germany 5.3.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Germany 5.3.3. Type-Specific Prevalence of Spinocerebellar Ataxia in the Germany 5.4. France 5.4.1. Total Prevalent Population of Spinocerebellar Ataxia in France 5.4.2. Total Diagnosed Cases of Spinocerebellar Ataxia in France 5.4.3. Type-Specific Prevalence of Spinocerebellar Ataxia in France 5.5. Italy 5.5.1. Total Prevalent Population of Spinocerebellar Ataxia in Italy 5.5.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Italy 5.5.3. Type-Specific Prevalence of Spinocerebellar Ataxia in Italy 5.6. Spain 5.6.1. Total Prevalent Population of Spinocerebellar Ataxia in Spain 5.6.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Spain 5.6.3. Type-Specific Prevalence of Spinocerebellar Ataxia in Spain 5.7. United Kingdom 5.7.1. Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom 5.7.2. Total Diagnosed Cases of Spinocerebellar Ataxia in the United Kingdom 5.7.3. Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom 5.8. Japan 5.8.1. Assumptions and Rationale 5.8.2. Total Prevalent Population of Spinocerebellar Ataxia in Japan 5.8.3. Total Diagnosed Cases of Spinocerebellar Ataxia in Japan 5.8.4. Type-Specific Prevalence of Spinocerebellar Ataxia in the Japan 6. Treatments 6.1. Potential treatments 6.2. U.S. Guidelines 6.2.1. Local Susceptibility of Host Tissue 6.3. Europe Guidelines 6.4. Management of Spinocerebellar Ataxia 7. Unmet Needs 8. Emerging Therapies 8.1. Troriluzole: Biohaven Pharmaceuticals 8.1.1. Product Description 8.1.2. Other Development Activities 8.1.3. Clinical Development 8.1.4. Safety and Efficacy 8.1.5. Product Profile 8.2. Rovatirelin (KPS-0373): Kissei Pharmaceutical 8.2.1. Product Description 8.2.2. Clinical Development 8.2.3. Safety and Efficacy 8.2.4. Product Profile 9. Other Promising Candidates 9.1. IB1001: IntraBio 9.1.1. Product Description 9.1.2. Other Development Activities 9.1.3. Clinical Development 9.1.4. Product Profile 9.2. Stemchymal: Steminent Biotherapeutics 9.2.1. Product Description 9.2.2. Other Development Activities 9.2.3. Clinical Development 9.2.4. Safety and Efficacy 9.2.5. Product Profile 10. Spinocerebellar Ataxia: 7 Major Market Analysis 10.1. Key Findings 10.2. Market Size of Spinocerebellar Ataxia in 7MM 11. The United States Market Outlook 11.1. United States Market Size 11.1.1. Total Market size of Spinocerebellar Ataxia 11.1.2. Market Size by Line of Therapies 12. EU-5 Countries: Market Outlook 12.1. Germany 12.1.1. Total Market size of Spinocerebellar Ataxia in Germany 12.1.2. Market Size by Line of Therapies 12.2. France 12.2.1. Total Market Size of Spinocerebellar Ataxia 12.2.2. Market Size by Line of Therapies 12.3. Italy 12.3.1. Total Market Size of Spinocerebellar Ataxia 12.3.2. Market Size by Line of Therapies 12.4. Spain 12.4.1. Total Market Size of Spinocerebellar Ataxia 12.4.2. Market Size by Line of Therapies 12.5. The United Kingdom 12.5.1. Total Market Size of Spinocerebellar Ataxia 12.5.2. Market Size by Line of Therapies 12.6. Japan: Market Outlook 12.7. Japan Market Size 12.7.1. Total Market Size of Spinocerebellar Ataxia 12.7.2. Market Size by Line of Therapies 13. Market Drivers 14. Market Barriers 15. Appendix 15.1. Report Methodology 16. DelveInsight Capabilities 17. Disclaimer 18. About DelveInsight

Table 1: SCA subtypes Table 2: SCA subtypes with associated clinical signs Table 3: Total Population of Spinocerebellar Ataxia in the 7MM (2017-2028) Table 4: Total Prevalent Population of Spinocerebellar Ataxia in the United States (2017-2028) Table 5: Total Diagnosed cases of Spinocerebellar Ataxia in the United States (2017-2028) Table 6: Type-Specific Prevalence of Spinocerebellar Ataxia in the United States (2017-2028) Table 7: Total Prevalent Population of Spinocerebellar Ataxia in Germany (2017-2028) Table 8: Total Diagnosed cases of Spinocerebellar Ataxia in Germany (2017-2028) Table 9: Type-Specific Prevalence of Spinocerebellar Ataxia in Germany (2017-2028) Table 10: Total Prevalent Population of Spinocerebellar Ataxia in France (2017-2028) Table 11: Total Diagnosed cases of Spinocerebellar Ataxia in France (2017-2028) Table 12: Type-Specific Prevalence of Spinocerebellar Ataxia in France (2017-2028) Table 13: Total Prevalent Population of Spinocerebellar Ataxia in Italy (2017-2028) Table 14: Total Diagnosed cases of Spinocerebellar Ataxia in Italy (2017-2028) Table 15: Type-Specific Prevalence of Spinocerebellar Ataxia in Italy (2017-2028) Table 16: Total Prevalent Population of Spinocerebellar Ataxia in Spain (2017-2028) Table 17: Total Diagnosed cases of Spinocerebellar Ataxia in Spain (2017-2028) Table 18: Type-Specific Prevalence of Spinocerebellar Ataxia in Spain (2017-2028) Table 19: Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom (2017-2028) Table 20: Total Diagnosed cases of Spinocerebellar Ataxia in the United Kingdom (2017-2028) Table 21: Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom (2017-2028) Table 22: Total Prevalent Population of Spinocerebellar Ataxia in Japan (2017-2028) Table 23: Total Diagnosed cases of Spinocerebellar Ataxia in Japan (2017-2028) Table 24: Type-Specific Prevalence of Spinocerebellar Ataxia in Japan (2017-2028) Table 25: Troriluzole ,Clinical Trial Description, 2019 Table 26: Rovatirelin ,Clinical Trial Description, 2019 Table 27: IB1001 ,Clinical Trial Description, 2019 Table 28: Stemchymal, Clinical Trial Description, 2019 Table 29: 7 Major Market Size of Spinocerebellar Ataxia in USD Million (2017-2028) Table 30: United States Market Size of Spinocerebellar Ataxia in the US, USD Million (2017-2028) Table 31: Market Size of Spinocerebellar Ataxia by Line of Therapies in the US, in USD Million (2017-2028) Table 32: Market Size of Spinocerebellar Ataxia in Germany, in USD Million (2017-2028) Table 33: Market Size of Spinocerebellar Ataxia by Line of Therapies in Germany, in USD Million (2017-2028) Table 34: Market Size of Spinocerebellar Ataxia in France, in USD Million (2017-2028) Table 35: Market Size of Spinocerebellar Ataxia by Line of Therapies in France, in USD Million (2017-2028) Table 36: Market Size of Spinocerebellar Ataxia in Italy, in USD Million (2017-2028) Table 37: Market Size of Spinocerebellar Ataxia by Line of Therapies in Italy, in USD Million (2017-2028) Table 38: Market Size of Spinocerebellar Ataxia in Spain, in USD Million (2017-2028) Table 39: Market Size of Spinocerebellar Ataxia by Line of Therapies in Spain, in USD Million (2017-2028) Table 40: Market Size of Spinocerebellar Ataxia in the UK, in USD Million (2017-2028) Table 41: Market Size of Spinocerebellar Ataxia by Line of Therapies in the UK, in USD Million (2017-2028) Table 42: Market Size of Spinocerebellar Ataxia in Japan, in USD, Million (2017-2028) Table 43: Market Size of Spinocerebellar Ataxia by Line of Therapies in Japan, in USD Million (2017-2028) Figure 1: SCA subtypes overall prevalence Figure 2: Repeat expansions that cause ataxia Figure 3: Harding’s classification of Spinocerebellar Ataxia, detailing the classification of SCA based on symptom presentation Figure 4: Common disease mechanisms underlying SCAs. Figure 5: Flowchart of molecular genetic diagnosis of SCAs Figure 6: Total Prevalent Patient Population of Spinocerebellar Ataxia in the 7MM (2017-2028) Figure 7: Total Prevalent Population of Spinocerebellar Ataxia in the United States (2017-2028) Figure 8: Total Diagnosed cases of Spinocerebellar Ataxia in the United States (2017-2028) Figure 9:Type-Specific Prevalence of Spinocerebellar Ataxia in the United States (2017-2028) Figure 10: Total Prevalent Population of Spinocerebellar Ataxia in Germany (2017-2028) Figure 11: Total Diagnosed cases of Spinocerebellar Ataxia in Germany (2017-2028) Figure 12:Type-Specific Prevalence of Spinocerebellar Ataxia in Germany (2017-2028) Figure 13: Total Prevalent Population of Spinocerebellar Ataxia in France (2017-2028) Figure 14: Total Diagnosed cases of Spinocerebellar Ataxia in France (2017-2028) Figure 15:Type-Specific Prevalence of Spinocerebellar Ataxia in France (2017-2028) Figure 16: Total Prevalent Population of Spinocerebellar Ataxia in Italy (2017-2028) Figure 17: Total Diagnosed cases of Spinocerebellar Ataxia in Italy (2017-2028) Figure 18:Type-Specific Prevalence of Spinocerebellar Ataxia in Italy (2017-2028) Figure 19: Total Prevalent Population of Spinocerebellar Ataxia in Spain (2017-2028) Figure 20: Total Diagnosed cases of Spinocerebellar Ataxia in Spain (2017-2028) Figure 21:Type-Specific Prevalence of Spinocerebellar Ataxia in Spain (2017-2028) Figure 22: Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom (2017-2028) Figure 23: Total Diagnosed cases of Spinocerebellar Ataxia in the United Kingdom (2017-2028) Figure 24:Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom (2017-2028) Figure 25: Total Prevalent Population of Spinocerebellar Ataxia in Japan (2017-2028) Figure 26: Total Diagnosed cases of Spinocerebellar Ataxia in Japan (2017-2028) Figure 27:Type-Specific Prevalence of Spinocerebellar Ataxia in Japan (2017-2028) Figure 28: Unmet Needs of Spinocerebellar ataxia Figure 29: 7 Major Market Size of Spinocerebellar Ataxia in USD Million (2017-2028) Figure 30: Market Size of Spinocerebellar Ataxia in the United States, USD Millions (2017-2028) Figure 31: Market Size of Spinocerebellar Ataxia by Line of Therapies in the US, in USD Million (2017-2028) Figure 32: Market Size of Spinocerebellar Ataxia in Germany, USD Million (2017-2028) Figure 33: Market Size of Spinocerebellar Ataxia by Line of Therapies, in Germany, in USD Million (2017-2028) Figure 34: Market Size of Spinocerebellar Ataxia in France, USD Million (2017-2028) Figure 35: Market Size of Spinocerebellar Ataxia by Line of Therapies, in France, in USD Million (2017-2028) Figure 36: Market Size of Spinocerebellar Ataxia in Italy, USD Million (2017-2028) Figure 37: Market Size of Spinocerebellar Ataxia by Line of Therapies in Italy, in USD Million (2017-2028) Figure 38: Market Size of Spinocerebellar Ataxia in Spain, USD Million (2017-2028) Figure 39: Market Size of Spinocerebellar Ataxia by Line of Therapies in Spain, in USD Million (2017-2028) Figure 40: Market Size of Spinocerebellar Ataxia in the UK, USD Million (2017-2028) Figure 41: Market Size of Spinocerebellar Ataxia by Line of Therapies in the UK, in USD Million (2017-2028) Figure 42: Market Size of Spinocerebellar Ataxia in Japan, USD Million (2017-2028) Figure 43: Market Size of Spinocerebellar Ataxia by Line of Therapies in Japan, in USD Million (2017-2028) Figure 44: Market Drivers Figure 45: Market Barriers

• Troriluzole (Biohaven Pharmaceuticals) • Rovatirelin (Kissei Pharmaceutical) • IB1001 (IntraBio) • Stemchymal (Steminent Biotherapeutics)